Gastrointestinal Cancer | Specialty

Recommendations for Molecular Testing in mCRC

February 14th 2019

EGFR Therapy for Right-Sided CRC

February 14th 2019

Dr. Eng on the Treatment Landscape in Metastatic Colorectal Cancer

February 13th 2019

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the treatment landscape in newly diagnosed metastatic colorectal cancer (mCRC).

Older Patients With Gastric Cancer May Derive Greater Benefit From Andecaliximab

February 9th 2019

Manish A. Shah, MD, discusses the results of the GAMMA-1 trial and challenges that remain for patients with gastric cancer.

Dr. Lee on Differences Between HIPEC and PIPAC in mCRC

February 9th 2019

Byrne Lee, MD, chief, Upper GI and Mixed Tumor Surgery Service, associate professor of surgical oncology, City of Hope, discusses the differences between HIPEC and PIPAC in the treatment of patients with metastatic colorectal cancer.

Microbial Metabolomics: A Search for the Missing Link to Cancer

February 8th 2019

Thanks to technological advances, the past several decades have witnessed a blossoming appreciation of the varied composition of these microbial communities, their complex and dynamic relationship with the host, and the way they affect health and disease.

Surgeon Highlights Regional Therapy Approaches for mCRC

February 8th 2019

Byrne Lee, MD, discusses regional treatment strategies for patients with metastatic colorectal cancer.

Novel Metabolic Therapy Demonstrates Activity in Metastatic Pancreatic Cancer

February 8th 2019

SM-88, a novel compound that attacks oncogenic metabolic pathways, is under development for patients with metastatic pancreatic cancer and other solid tumors, raising the potential for a tumor-agnostic therapy.

Overcoming Challenges in the Management of mCRC

February 8th 2019

Later-Line Treatment for mCRC: Regorafenib or TAS-102?

February 8th 2019

mCRC: Stratifying Patients to Appropriate Therapy

February 8th 2019

Improving Molecular Understandings of mCRC

February 8th 2019

Metastatic Colorectal Cancer: Frontline Treatment Paradigm

February 8th 2019

Dr. Mody Highlights Treatment Advances in HCC

February 8th 2019

Kabir Mody, assistant professor of medicine, consultant, Division of Hematology/Oncology, Mayo Clinic, highlights the recent treatment advances for patients with hepatocellular carcinoma.

Future of CRC Rests in Greater Genomic Understanding

February 7th 2019

Marwan Fakih, MD, discusses recent trials in colorectal cancer and highlights other ongoing research in the field.

Dr. Li on Preoperative Immunotherapy in Hepatocellular Carcinoma

February 6th 2019

Daneng Li, MD, an assistant clinical professor in the Department of Medical Oncology and Therapeutics Research, and a medical oncologist at City of Hope, discusses an ongoing study of preoperative immunotherapy in patients with hepatocellular carcinoma (HCC).

Dr. Kasi on the Application of Pharmacogenomics in CRC

February 5th 2019

Pashtoon M. Kasi, MD, MBBS, MS, assistant professor of oncology and senior associate consultant in the Division of Hematology/Oncology at Mayo Clinic, discusses the application of pharmacogenomics in colorectal cancer (CRC).

Targeted Therapies, Triplet Regimens Becoming Focus in Biliary Tract Cancers

February 5th 2019

Rachna T. Shroff, MD, MS, highlighted the ongoing research efforts in biliary tract cancers, specifically with cholangiocarcinoma treatment.

Online Tool Estimates the Risk for Lynch Syndrome

February 5th 2019

Because specific risk-reducing interventions may be available, it is important to identify individuals with germline variants in cancer susceptibility genes.

Further Evidence Needed Supporting Clinical Utility of Liquid Biopsies in GI Cancers

February 5th 2019

John Strickler, MD, discusses how liquid biopsies are being used to help guide treatment decisions for patients with GI cancers and shed light on other research efforts that are being made to improve outcomes.